💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
Hang Likang: Currently, there is only one innovative drug project under research.
Jin10 Data July 1st, Anglikon released an announcement regarding abnormal fluctuations in stock trading. The company has noticed that the market’s attention on innovative drug business has been relatively high recently. Currently, the company has only one innovative drug project under research, which is the ALK-N001 project. This project received a notice of approval for clinical trials in April 2025, and as of the date of this announcement, it is still in the Phase I clinical trial stage. The development of innovative drugs is characterized by long cycles, high investment, and high uncertainty, and investors are advised to pay attention to investment risks.